Moderna’s Q1 trading driven by Covid vaccine sales

The US company has reported revenues of $6.07bn in the first quarter, compared with expectations of $4.62bn. The rise in turnover has been driven by Moderna's Covid-19 vaccine, whose sales more than tripled to $5.9bn from the $1.7bn posted last year.

Read the full article.